文献速递免疫规划慢病防控与筛查

儿童风湿病循环CXCR5+辅助T细胞比例改变不影响流感疫苗应答

Altered proportions of circulating CXCR5+ helper T cells do not dampen influenza vaccine responses in children with rheumatic disease.
PubMed 文献 · Vaccine · 2019-05-22

在连续3个流感季节中,研究评估了78例儿童风湿病(PRD)患者(17例未治疗、61例接受甲氨蝶呤、TNF抑制剂或IL抑制剂治疗)及24例健康对照对三价流感疫苗(TIV)的抗体应答,并检测免疫前外周B细胞、T细胞、NK细胞、CXCR5+滤泡辅助T细胞(TFH)及相关趋化因子。未治疗PRD患儿TFH比例显著低于治疗患者和健康对照,血清CXCL13水平显著升高,但TFH比例或CXCL13水平均不能预测TIV抗体应答,PRD患儿总体应答与健康儿童相似。

要点

  • 未治疗PRD患儿循环TFH比例显著低于治疗患者和健康对照,血清CXCL13显著升高。
  • 免疫时TFH比例或CXCL13水平不能预测儿童对TIV的抗体应答。
  • PRD患儿对TIV的总体应答与健康儿童相似,但TNF抑制剂组有少数儿童对H3N2和乙型流感保持血清阴性。

核心结论

  • 儿童风湿病患者对三价流感疫苗的应答与健康儿童总体相似。
  • 循环TFH比例改变及CXCL13水平升高不削弱流感疫苗抗体应答。

研究设计与样本

  • 连续3个流感季节的流感疫苗研究,评估儿童风湿病患者(n=78,其中未治疗17例、治疗61例)及健康年龄匹配对照(n=24)对TIV的抗体应答。
  • 治疗包括甲氨蝶呤、TNF抑制剂(联合或不联合甲硝蝶呤)或IL抑制剂。
  • 免疫前检测外周B细胞、T细胞、NK细胞、CXCR5+滤泡辅助T细胞及参与抗体应答的趋化因子。

主要发现

  • 未治疗PRD患儿循环TFH细胞比例显著低于治疗患者和健康对照。
  • 未治疗PRD患儿血清CXCL13水平显著高于治疗患者和健康对照。
  • 免疫时TFH比例或CXCL13水平不能预测该儿童队列对TIV的抗体应答。
  • PRD患儿对TIV的总体应答与健康儿童相似。
  • 接受TNF抑制剂治疗的儿童中,少数在免疫后对H3N2和乙型流感病毒仍保持血清阴性,但差异不显著。

临床怎么用

  • 儿童风湿病患者可按推荐接种流感疫苗,整体抗体应答与健康儿童相似。
  • 接受TNF抑制剂治疗的患儿接种后个别可能对H3N2或乙型流感保持血清阴性,可关注免疫效果。

局限性

  • TNF抑制剂组少数儿童保持血清阴性的差异未达统计学显著。
  • 免疫前CXCL13水平与TFH比例或免疫后抗体应答均不相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biological therapy options for the treatment of rheumatic disease target molecules that can affect the cross-talk between innate and adaptive immune responses upon vaccination. Influenza vaccination in children with rheumatic disease has been recommended, but there are only sparse data on the quality of vaccine responses from pediatric patients treated with biological therapy. We conducted an influenza vaccine study over 3 consecutive seasons where the antibody response to TIV was evaluated in children with PRD (n = 78), including both non-treated (n = 17) and treated (with methotrexate, TNF-inhibitors with or without methotrexate, or IL-inhibitors, n = 61) children as well as healthy age-matched controls (n = 24). Peripheral B cells, T and NK cell populations, as well as CXCR5+ (follicular) helper T cells (TFH) and chemokines involved in antibody responses were assessed prior to immunization in the same cohort. Data on disease duration, therapy and data on previous influenza vaccinations were retrieved. The proportion of circulating TFH cells were significantly lower in non-treated children with PRD compared to treated patients and healthy controls. The significantly lower proportion of TFH cells was mirrored by a marked significant increase in CXCL13 serum level, the ligand for CXCR5, with higher levels in non-treated children with PRD compared to treated patients and healthy controls. However, the proportion of TFH cells or CXCL13 level at the time of vaccination was not a predictor of the antibody response to TIV in this cohort of children. Children with PRD had an overall similar response to TIV as healthy children. Although not significant, children treated with TNF-inhibitors differed as a few children remained seronegative towards H3N2- and influenza B viruses after immunization. Our data show that children with PRD respond to TIV as healthy children. Furthermore, plasma CXCL13 levels did not correlate to the proportion of TFH cells in blood prior to immunisation, or to antibody responses following immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Laestadius Å, Ingelman-Sundberg HM, Myrberg IH, et al. Altered proportions of circulating CXCR5+ helper T cells do not dampen influenza vaccine responses in children with rheumatic disease. Vaccine. 2019. PMID: 31126860. doi:10.1016/j.vaccine.2019.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。